Patients with primary hyperoxaluria type 2 have significant morbidity and require careful follow-up
Sander F. Garrelfs(Emma Kinderziekenhuis), Sally‐Anne Hulton(Birmingham Children's Hospital), Eduardo Salido(Universidad de La Laguna), Michiel J.S. Oosterveld(Emma Kinderziekenhuis), Florian Erger(University of Cologne), Graham Lipkin(Queen Elizabeth II Medical Centre), Pierre Cochat(Société Nationale des Chemins de Fer Français (France)), Hessel Peters‐Sengers(Amsterdam Neuroscience), Bernd Höppe(University of Bonn), Bodo B. Beck(University of Cologne), Brigitte Adams(Queen Fabiola Children's University Hospital), Gill Rumsby(University College London Hospitals NHS Foundation Trust), Alessandra Pelle(Ospedale San Luigi Gonzaga), Thomas J. Neuhaus(University of Zurich), Jaap W. Groothoff(University of Amsterdam)
Cited by 103
Related Papers
Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis
|Nature Medicine|2011|834
The centrosomal protein nephrocystin-6 is mutated in Joubert syndrome and activates transcription factor ATF4
|Nature Genetics|2006|573
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
|New England Journal of Medicine|2021|505
History, epidemiology and regional diversities of urolithiasis
|Pediatric Nephrology|2008|460
SIX1 mutations cause branchio-oto-renal syndrome by disruption of EYA1–SIX1–DNA complexes
|Proceedings of the National Academy of Sciences|2004|420